Case Series of Thrombosis with Thrombocytopenia Syndrome following COVID-19 vaccination—United States, December 2020–August 2021

Data Sources

The Vaccine Adverse Events Reporting System (VAERS) is a passive surveillance (spontaneous reporting) system for adverse events following immunization jointly administered by the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) [18]. VAERS accepts all reports of possible adverse events following vaccination from patients, clinicians, vaccine manufacturers, and the public, regardless of clinical severity of the event or its causal association with vaccination. The VAERS database was searched for potential reports of TTS received during December 14, 2020 through August 31, 2021, in the following manner: 1) on April 9, 2021, a retrospective search was conducted for reports received during December 14, 2020 through April 8, 2021; 2) prospective searches were conducted beginning on April 9, 2021. All data for this report were retrieved by August 31, 2021. Reports were screened for Medical Dictionary for Regulatory Activities (MedDRA) standardized codes (Preferred Terms [PTs]) [19] assigned to reports by professional medical coders, as well as language in the symptom or laboratory text fields of the report, that described symptoms, laboratory values, and medical conditions that could indicate TTS (see Supplemental Methods).

Vaccine administration data were reported by public health jurisdictions to CDC (Supplemental Methods) [20].

Case definitions

We used the following case definitions for TTS. A Tier 1 case had thrombosis in an unusual location for a thrombus (i.e., cerebral vein, visceral artery or vein, extremity artery, central artery or vein) and new-onset thrombocytopenia (i.e., platelet count <150,000/µL) occurring any time after receipt of a COVID-19 vaccine. Tier 2 cases had new-onset thrombocytopenia, thrombosis in an extremity vein or pulmonary artery in the absence of thrombosis at a Tier 1 location, and a positive anti-PF4 antibody ELISA test or functional HIT platelet test occurring any time after receipt of COVID-19 vaccine. Given the very unusual clinical presentation of the Tier 1 cases, additional laboratory abnormalities were not required, whereas the inclusion of positive HIT testing results for cases with only common thromboses (Tier 2) was intended to limit the number of potential false positive cases.

Confirmation of case status required review of patient data from medical records and in some cases also discussion with providers. All cases were also reviewed with clinicians from CDC’s Clinical Immunization Safety Assessment (CISA) Project (Supplemental Methods) [21].

Data analysis

TTS reporting rates were calculated per million doses of Ad26.COV2.S vaccine administered and stratified by sex and age group. Overall reporting rates were calculated per million mRNA COVID-19 vaccine (i.e., Moderna and Pfizer-BioNTech) doses administered. Booster dose administration was excluded from reporting rate calculations.

Data were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at CDC. REDCap is a secure, web-based software platform designed to support data entry and management [22,23]. Descriptive analysis of demographic and clinical data associated with TTS cases was conducted. Demographics, risk factors for thrombosis, platelet nadir, and timing of clinical presentation were compared between Tier 1 and Tier 2 cases using chi-square or Fisher’s exact test, as appropriate, for categorical variables and using Wilcoxon rank-sum test for continuous variables. To permit comparisons with other reports concerning TTS, supplemental results describe whether cases met definite or probable VITT criteria established by the United Kingdom (UK) Expert Hematology Panel [17]. Venous thromboembolism risk factors were assessed according to published literature [24-25]. Data analyses were conducted with SAS 9.4 (SAS Institute, Cary, NC).

Human subjects

This activity was reviewed by the CDC Human Subjects Office, determined to be a non-research public health surveillance project, and was conducted consistent with applicable federal law and policy (see e.g., 45 C.F.R. part 46.102(I)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq).

Role of the Funding source

This activity was funded by CDC. CDC and non-CDC co-authors conducted the investigations; performed collection, management, analysis, and interpretation of the data; were involved in preparation, review, and approval of the manuscript; and made the decision to submit the manuscript for publication.

TTS reporting rates

Of 579,301 total reports to VAERS after COVID-19 vaccination during the analytic period, 1,122 were identified as potential cases based on initial screening of VAERS reports. Of these, 51 are pending adjudication, 6 had insufficient information was contained in the report to determine (e.g., the report included information about thrombosis only and no provider listed to obtain further information) and 953 did not meet case definition criteria. Of the 112 remaining reports, confirmed to have thrombosis and thrombocytopenia after COVID-19 (i.e., potentially meeting criteria for the TTS case definition), 66 reports were excluded because they were duplicate reports (n=30); active COVID-19 infection was documented at the time of TTS diagnosis (n=5); thrombocytopenia was not new-onset (n=2); TTS symptoms preceded COVID-19 vaccination (n=3); thrombocytopenia was most likely artifactual (n=1); or thrombosis was more likely due to another cause (n=19). After these exclusions, 52 reports were determined to meet the CDC case definition for TTS: 50 cases after Ad26.COV2.S and 2 after mRNA COVID-19 vaccination (Figure 1).

• Download figure
• Open in new tab

Figure 1:

Reports to the Vaccine Adverse Event Reporting System (VAERS) confirmed to be thrombosis with thrombocytopenia syndrome (TTS), United States, December 2020–August 2021

Given administration of 14.1 million doses of Ad26.COV2.S and 351 million doses of mRNA COVID-19 vaccines, the overall TTS reporting rate (per million vaccine doses administered) was 3.55 after Ad26.COV2.S and 0.0057 after mRNA COVID-19 vaccination. Reporting rates were highest following receipt of Ad26.COV2.S vaccine among females aged 30-39 years (10.6 per million doses) and 40-49 years (8.12 per million doses) (Table 1).

Demographics, location of thrombosis, treatment, and outcomes of TTS cases following Ad26.COV2.S vaccination

The 50 TTS cases reported following Ad26.COV2.S vaccination occurred in patients with median age of 43.5 years (range: 18-70; interquartile range 36-52); 35 (70%) were female and 37 (74%) were white (Table 2). Forty-two cases were Tier 1 (84%) and 8 (16%) were Tier 2. Either a venous thrombosis or thromboembolism was found in 49/50 cases (98%). The most common anatomic region for thrombosis was cerebral venous sinuses (n=27; 54%). Eight TTS cases (16%) had arterial thrombosis (including 7 also with a venous thrombosis or thromboembolism). Thrombosis was present in more than one anatomic region for 36 cases (52%). A recognized risk factor for venous thromboembolism [24-25] was present in 33 (66%) of cases, most commonly obesity (n=23; 46%). No TTS cases occurred in females who were pregnant or within 12 weeks postpartum, or in patients with known thrombophilia. Seven cases (14%) occurred in patients with prior SARS-CoV-2 infection; demographics, presence of risk factors for venous thrombosis, and timing of illness did not differ significantly between cases with cerebral venous sinus thrombosis and other cases (Supplemental Table 1).

Heparin was administered to manage thrombosis in 11/13 cases (85%) presenting before the pause in use of Ad26.COV2.S and 10/37 (27%) of the cases presenting after. Other treatments used to manage TTS were non-heparin anticoagulants (n=46; 92%), intravenous immunoglobulin (n=33; 66%), corticosteroids (n=21; 42%), platelet transfusion (n=18; 36%), and plasmapheresis (n=3; 6%). A surgical or radiologic procedure was performed in 20 cases (40%) to manage thrombosis or suspected complication, of which the most common was thrombectomy or catheter-directed thrombolysis (n=15; 30%).

All patients were hospitalized; 32 (64%) were admitted to an intensive care unit (ICU). Outcomes of the initial hospitalization were discharge home (n=36; 72%), discharge to post-acute care facility (n=8; 16%), and death (n=6; 12%). For patients discharged from the hospital alive, median hospital length of stay was 6 days (range: 1-132 days) (Supplemental Figure 1).

All sixr deaths occurred in non-Hispanic white patients with cerebral venous sinus thrombosis; five had superior sagittal sinus thrombosis. Four decedents were female; ages ranged from 29-52 years (median: 41 years). Four of the decedents had underlying medical conditions (n=4 with a risk factor for venous thromboembolism [obesity]; n=1 with asthma; n=1 with hyperlipidemia; n=1 with seizure disorder). None had documentation of prior SARS-CoV-2 infection. None received heparin. All had cerebral hemorrhage and evidence of mass effect on initial neuroimaging and died within 2 days of presentation. Median platelet count nadir among decedents was 15,500/µL (range: 9,000-44,000/µL). Anti-PF4 antibody ELISA testing was performed for four decedents; all tests were positive with optical density values >2.0.

Laboratory findings and clinical presentation of TTS cases following Ad26.COV2.S vaccination

Symptoms began a median of 10 days after vaccination (range: 0-18 days) (Table 2; Supplemental Table 2). The most common initial symptom reported among cases was headache (n=35; 70%); headache was an initial symptom for 24/27 (89%) of cases with cerebral venous sinus thrombosis and for 11/23 (48%) of cases without cerebral venous sinus thrombosis (Supplemental table 2). Nineteen (38%) patients had at least one prior healthcare encounter for evaluation of symptoms with discharge home prior to a hospital admission and TTS diagnosis; of these, 9 were documented to have thrombocytopenia during the initial encounter (i.e., before hospital admission). In 7 cases, radiologic evaluation on initial presentation was negative for thrombosis, including 5 (of whom one later died) with initial radiologic examination negative at a site where thrombosis was later diagnosed (e.g., negative initial computed tomography venogram of the head in a patient later found to have cerebral venous sinus thrombosis on imaging).

Thrombocytopenia was present during TTS hospitalization with the exception of one case of pulmonary embolism in which thrombocytopenia was found only at the first emergency department visit following Ad26.COV2.S vaccination. The platelet count had returned to normal by the time the patient was hospitalized 6 days later with pulmonary embolism and a positive anti-PF4 antibody ELISA test.

The median platelet nadir was 32,500/µL (range: 5,000-127,000) (Table 4; Supplemental Figure 3). Platelet nadirs differed by clinical characteristics and course of disease. All patients with hospital length of stay >20 days (n=6) had platelet count nadirs <25,000/µL (Supplemental figure 4). All patients who were admitted to the hospital >12 days after symptom onset (n=6) had platelet nadirs >75,000/µL (Supplemental figure 5). Median platelet nadir for cases admitted to the ICU was 27,500/µL (range: 5,000-127,000/µL) vs 44,000/µL for cases not admitted to the ICU (range: 8,000-112,000/µL). For 39 patients discharged from the hospital alive with discharge platelet counts available, median platelet count at discharge was 167,000/µL (range: 91,000-469,000/µL) (Table 4). Of these patients, 16 (41%) had platelet count <150,000/µL at discharge.

Anti-PF4 antibody ELISA results were positive in 42 (84%), negative in 3 (6%), and not performed in 5 (10%) cases (Table 4). Functional HIT platelet testing results were available for 34 and positive in 11. Of the three TTS cases following Ad26.COV2.S vaccination with negative anti-PF4 antibody ELISA results, two occurred in male patients; two were Hispanic or non-white race. All had underlying medical conditions, including hyperlipidemia (n=2) and prior vascular disease (n=2; history of myocardial infarction or ischemic stroke). All had platelet nadir >100,000/µL. Two had cerebral venous sinus thrombosis and one had abdominal vein thrombosis.

A thrombophilia evaluation (including testing for one or more of the following: lupus anticoagulant; cardiolipin, β₂-glycoprotein I, phosphatidylserine antibodies; prothrombin G20210A mutation; Factor V Leiden mutation) was reported for 30 cases (60%); results for these 30 did not suggest an alternative cause for thrombosis (Table 4).

Supplemental Results describe evaluation of U.S. TTS cases following Ad26.COV2.S vaccination using the U.K. Expert Hematology Panel VITT case definition.

Description of TTS cases following mRNA COVID-19 vaccination

Two TTS cases were identified following mRNA COVID-19 vaccination, both after dose 2 of the Moderna COVID-19 Vaccine. Both occurred in males aged over 50 years who were either non-white or Hispanic and had cardiovascular risk factors (hyperlipidemia and hypertension in both; diabetes in one). Both had cerebral venous sinus thrombosis, and one also had deep vein thrombosis and pulmonary emboli. Symptom onset occurred 2 and 11 days after vaccination. Platelet nadirs were <25,000/µL for one case and between 50,000-100,000/µL for the other. Anti-PF4 antibody ELISA results were positive with optical density values >2.0. One patient received intensive care and died during hospitalization; the other was discharged home.